IMMX (Immix Biopharma) Days Payable: 0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMMX Immix Biopharma Inc IMMX
22 GF Score
Price $13.67
! 2 Warning Signs
View Full Analysis

What is Immix Biopharma Days Payable?

Immix Biopharma IMMX +3.80% 22 Days Payable is 0.00 as of Jun. 2026. GuruFocus rates IMMX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 704 Biotechnology companies, Immix Biopharma ranks worse than 142045.31% on this metric.

Immix Biopharma's average Accounts Payable for the three months ended in Jun. 2026 was $5.01 Mil. Immix Biopharma's Cost of Goods Sold for the three months ended in Jun. 2026 was $0.00 Mil.

The historical rank and industry rank for Immix Biopharma's Days Payable or its related term are showing as below:

IMMX's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 110.01
* Ranked among companies with meaningful Days Payable only.

Immix Biopharma's Days Payable stayed the same from Jun. 2025 (0.00) to Jun. 2026 (0.00). stayed the same

Immix Biopharma Days Payable Historical Data

* Premium members only.

The historical data trend for Immix Biopharma's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immix Biopharma Days Payable Chart

Immix Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Days Payable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Immix Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Days Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IMMX vs CBIO, NVCT, ALLO: Days Payable Comparison

For the Biotechnology subindustry, Immix Biopharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immix Biopharma Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immix Biopharma's Days Payable distribution charts can be found below:

* The bar in red indicates where Immix Biopharma's Days Payable falls into.


IMMX
22GF Score
Immix Biopharma Inc IMMX
Days Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immix Biopharma Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Immix Biopharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

Days Payable (A: Dec. 2025 )
=Average Accounts Payable /Cost of Goods Sold*Days in Period
=( (Accounts Payable (A: Dec. 2024 ) + Accounts Payable (A: Dec. 2025 )) / count ) / Cost of Goods Sold (A: Dec. 2025 )*Days in Period
=( (5.388 + 5.443) / 2 ) / 0*365
=5.4155 / 0*365
=N/A

Immix Biopharma's Days Payable for the quarter that ended in Jun. 2026 is calculated as:

Days Payable (Q: Jun. 2026 )
=Average Accounts Payable / Cost of Goods Sold*Days in Period
=( (Accounts Payable (Q: Mar. 2026 ) + Accounts Payable (Q: Jun. 2026 )) / count ) / Cost of Goods Sold (Q: Jun. 2026 )*Days in Period
=( (4.73 + 5.28) / 2 ) / 0*365 / 4
=5.005 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Days Payable →
What does a Days Payable of 0.00 mean?
Immix Biopharma (IMMX) has a Days Payable of 0.00 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Immix Biopharma and its competitors. According to the industry distribution chart, Immix Biopharma ranks #999999 out of 704 companies in the Biotechnology industry.
Is Immix Biopharma's Days Payable too high?
Immix Biopharma's current Days Payable is 0.00. Based on the distribution chart, Immix Biopharma ranks #999999 out of 704 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Immix Biopharma has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Immix Biopharma's Days Payable compare to CBIO and NVCT?
According to the Biotechnology industry distribution chart, Immix Biopharma ranks #999999 out of 704 companies for Days Payable. This places Immix Biopharma in the lower half of its industry. The industry median Days Payable is 110.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.01, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Immix Biopharma and its competitors. For the Biotechnology industry, the median Days Payable is 110.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immix Biopharma's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immix Biopharma stock overvalued right now?
Immix Biopharma (IMMX) has a current Days Payable of 0.00. The current Days Payable is 0.00. Immix Biopharma's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Immix Biopharma (IMMX), the current Days Payable is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immix Biopharma Business Description

Address 11400 West Olympic Boulevard, Suite 200, Los Angeles, CA, USA, 90064
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
22GF Score

Get the complete analysis for IMMX

Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.67
Price